INTRODUCTION
The target of rapamycin (TOR) pathway is only found in eukaryotes and is conserved in multiple species from yeast to mammals. 1 It was originally discovered by the recognition of mutations that conferred resistance to the growth inhibitory effects of rapamycin in the yeast, Saccharomyces cerevisiae. 2 The mammalian TOR (mTOR) was identified later, when multiple groups cloned the mTOR gene in mouse, human and rat. [3] [4] [5] [6] [7] TOR is present in at least two unique complexes with other proteins, TOR complex 1 (TORC1) and TOR complex 2 (TORC2). 8, 9 These complexes are differentially regulated by distinct upstream signals, and their activation and functional engagement results in control of distinct downstream effector pathways. Nutrients, growth factors, cellular energy and stress pathways regulate TORC1, while TORC2 appears to be primarily regulated by growth factors. 8, 10, 11 Recently, it was also shown that interferons (IFNs), which are cytokines with growth inhibitory activities, could also activate mTORC1 12 and mTORC2. 13 Other work has demonstrated that mTORC2 is inhibited by ER stress through phosphorylation of rapamycin-insensitive companion of mTOR (RICTOR) by glycogen synthase kinase 3b (GSK-3b).
14 These complexes have distinct functions, with TORC1 primarily acting as regulator of cell growth, protein synthesis and autophagy, whereas TORC2 controls cellular events important for cytoskeletal rearrangement, cell survival, cell-cycle progression and metabolism. 15 REGULATION AND FUNCTION OF mTORC1 AND mTORC2 mTORC1 mTORC1 in mammals is composed of regulatory-associated protein of mTOR (RAPTOR), 40 kDa proline-rich AKT substrate (PRAS40), DEP domain-containing mTOR-interacting protein (DEP-TOR), and mammalian lethal with SEC13 protein 8 (mLST8), with RAPTOR and PRAS40 being the unique components, while the rest are shared with mTORC2. 15 The major substrates for mTORC1 are the p70 S6 kinase (S6K) and the translational repressor eIF4E-binding protein 1 (4E-BP1). [16] [17] [18] mTORC1 activity is required for phosphorylation and subsequent activation of S6K, which then phosphorylates or binds proteins such as eukaryotic elongation factor 2 kinase (eEF2K), S6K Aly/REF-like target (SKAR), ribosomal protein S6 (rpS6) and eukaryotic initiation factor 4B (eIF4B), ultimately promoting translation initiation and elongation. [19] [20] [21] Recently, a new substrate for S6K has been discovered, gliomaassociated oncogene homolog 1 (GLI1), which links mTORC1 to Hedgehog signaling. 22 Thus, several distinct substrates are phosphorylated by S6K, resulting in activation of diverse downstream signals, reflecting a multifaceted role for S6K as a major branch of the mTOR pathway. mTORC1 also phosphorylates and deactivates 4E-BP1, which in its unphosphorylated form inhibits mRNA translation initiation by binding to the eukaryotic initiation factor 4E (eIF4E). [23] [24] [25] Upon phosphorylation by mTORC1, 4E-BP1 dissociates from eIF4E and allows eIF4E binding to eIF4G, so initiation of translation can occur. [24] [25] [26] mTORC1 activity can be controlled by multiple growth factor and cytokine pathways. 12, [27] [28] [29] [30] [31] AKT activates mTORC1 via phosphorylation and inhibition of tuberous sclerosis 1/2 (TSC1/2), which leads to RAS homolog enriched in brain (RHEB) activation. 27, 30 Extracellular signal-related kinase (ERK) and 90 kDa ribosomal protein S6 kinase 1 (RSK1), have been also shown to phosphorylate/inactivate the TSC1/2 complex, suggesting that they may also regulate mTORC1. 29, 31 The WNT pathway can also control mTORC1 activity by inhibition of GSK-3b, which inhibits mTORC1 via phosphorylation/activation of TSC2.
Also, mTORC1 can be regulated by cellular energy through AMPactivated protein kinase (AMPK). 33, 34 AMPK can inhibit mTORC1 by phosphorylating and activating TSC2. 32, 35 AMPK has been also shown to directly phosphorylate RAPTOR, and affect mTORC1 complex formation. 36 The AMPK phosphorylation sites in RAPTOR are highly conserved in all eukaryotes, even in those lacking the TSC complex, indicating it was probably the first mechanism to link AMPK to TOR. 36 It should be noted that a direct interaction between RAPTOR and AMPK, however, has only been shown in mammals.
36 mTORC1 can be inhibited by DNA damage or other cellular stress signals through the p53 response by upregulating the expression of negative regulators of PI3K/mTOR. 37 Also p53 has been shown to upregulate the genes for Sestrin1 and Sestrin2, which activate AMPK, thus inhibiting mTORC1. 38 Another potential regulator of mTORC1 is PRAS40. This protein was originally discovered as a substrate for AKT, 39, 40 and then subsequently shown to be a component and substrate of mTORC1. [41] [42] [43] [44] There have been studies to show that it can act as either a negative or positive regulator of mTOR signaling, likely depending on the context of engagement and the activation or interference of other signaling elements. 41, 42, [44] [45] [46] [47] Therefore, its specific role in mTOR signaling remains to be clarified and precisely defined.
The precise mechanism of mTORC1 regulation by amino acids is not known. However, it has been established that the amino acid levels can affect mTORC1 activity through VPS34 and RAG GTPases. 15, 48 Amino acids cause a switch of RAGs to their active conformation by promoting their conversion to their proper GTP/GDP-bound state. 49, 50 The active RAGs then bind to RAPTOR and target mTORC1 to the endosome and lysosome where it can be activated by RHEB in response to amino acids. 50 RHEB is required for activation of mTORC1 by amino acids independent of the TSC complex, unlike insulin, which requires both RHEB and TSC1/2. 27, 51 VPS34 is a class III PI3K that was recently shown to be critical for the process of autophagy, by forming a complex with BECLIN1 and UV radiation resistance-associated gene protein (UVRAG) 52, 53 ( Figure 1 ). Two independent studies have also established that amino acids stimulate VPS34 activity, which in turn activates S6K. 51, 54 Whether VPS34 directly activates S6K or mTORC1 is not known, but mTORC1 has been co-immunoprecipitated with VPS34, 48 suggesting a regulatory effect at the mTORC1 level. Under energy stress, AMPK is also able to inhibit VPS34, which indicates that both amino acids and energy levels can regulate mTORC1 through VPS34. 54 The role of VPS34 in autophagy and mTORC1 signaling seems counterintuitive as mTORC1 is established as a key negative regulator of autophagy 48 ( Figure 1) . Thus, the precise regulation and engagement of VPS34 in both processes remains to be investigated. It should be noted, that both mTORC1 and mTORC2 can regulate autophagy, but only mTORC1 does so directly (Figure 1 ). Whereas AMPK can phosphorylate ULK1 to activate autophagy, mTORC1 can directly phosphorylate ULK1 to inhibit autophagy. 55, 56 On the other hand, mTORC2 has been reported to inhibit autophagy indirectly, via repression by the AKT/forkhead box protein O (FOXO) axis of certain genes encoding for elements of the autophagic machinery.
mTORC2
The mTORC2 complex is composed of mammalian stress-activated map kinase-interacting protein 1 (mSIN1), protein observed with RICTOR (PROTOR), RICTOR, DEPTOR and mLST8, where the unique complex components are mSIN1, PROTOR and RICTOR.
15 mTORC2 phosphorylates AGC kinases, such as AKT, serum and glucocorticoid-regulated kinase (SGK) and protein kinase C-a (PKCa). [58] [59] [60] [61] A defining function of the mTORC2 complex is its ability to phosphorylate AKT on the Ser473 (Ser505 in flies) residue, priming AKT for further phosphorylation by 3-phosphoinositide-dependent protein kinase 1 (PDK1) at the Thr308 residue. 58, 60, 61 The integrity of RICTOR is essential for such AKT phosphorylation and RICTOR knockout cells exhibit defective phosphorylation of AKT at Ser473 in response to induction by a variety of stimuli. 13, 61, 62 Loss of phosphorylation at the Ser473 site, however, only affects some of its substrates such as the FOXOs but not TSC2, in response to growth factor signaling. 62 However, it may have different implications in signaling for certain cytokines, as in the IFN-system it appears that phosphorylation of certain mTOR effectors such as S6K and 4E-BP1 is impaired in the absence of RICTOR, suggesting differential effects on AKT Ser473 phosphorylation on downstream mTORC1 signaling by IFNs, as compared with growth factor signals. 13 mSIN1 is required for the function and activity of mTORC2. [63] [64] [65] mSIN1 is also directly phosphorylated by mTOR, which prevents its degradation by the lysosome. 66 mSIN1 exists in multiple splice variants. 67 Only three of them can be incorporated into mTORC2 (Sin 1.1, 1.2 and 1.5) and regulate AKT phosphorylation. 63 The different spliced forms make up distinct mTORC2 complexes as only two of them can be stimulated by insulin, indicating that these distinct complexes respond differently to upstream stimuli. 63 The identity of the physiological activator of mTORC2 complexes containing Sin 1.5 remains elusive at this time.
The precise role of PROTOR in mTORC2 structure and function is not well known. There are two isoforms of this protein, PROTOR1 and PROTOR2. 43, 68 PROTOR knockout had no obvious effects on mTORC2 assembly or function. 43, 68, 69 PROTOR1 knockdown in cells impairs platelet-derived growth factor (PDGF)-dependent induction of AKT and S6K phosphorylation, with modest effects on insulin or epidermal growth factor (EGF)-dependent phosphorylation, due to a PDGF receptor b leading to an effect on cell proliferation rates. 68 PROTOR2 knockdown in cells leads to a resistance to apoptosis and PROTOR2 dissociates from mTORC2 when TSC1/2 is knocked down. 43 Knockout mice for both the Protor1 and Protor2 genes were recently generated, in an attempt to better elucidate their function. Surprisingly, the only defect was a decrease in activation of SGK1 and its downstream effector, N-myc downstream regulated 1 (NDRG1), Figure 1 . Role of mTOR in autophagy. mTORC1 inhibits autophagy by directly phosphorylating ULK1, while AMPK activates autophagy by directly phosphorylating ULK1. ULK1 forms a complex with FIP2000 and ATG13, leading to induction of autophagy. AMPK can inhibit mTORC1 directly or through VPS34. VPS34 can lead to activation of S6K; however, it is unknown whether it does so directly or via mTORC1 engagement. VPS34 activates autophagy by binding to Beclin 1 and UVRAG. mTORC2 can indirectly inhibit autophagy by engaging AKT which inhibits FOXOs. Autophagy inhibitors such as chloroquine or bafilomycinA1 could be conceivably used in combination with mTOR inhibitors to more effectively target malignant cells.
in kidney cells of Protor 1-deficient mice only. 69 Why PROTOR1 only affects mTORC2 in the kidney remains to be definitively established, but it may simply reflect a dependence of kidney cells on SGK1 signaling. 69 However, it is also possible that PROTOR exhibits effects on other mTORC2 substrates and tissues not investigated in that study. 69 mSIN1 and RICTOR associate with each other to form a heterodimer that then binds mTOR. 63, 64 PROTOR also binds RICTOR, but does so independently of the mTOR-RICTOR interaction. 43, 68 Recent evidence has shown that a specific residue, Gly934, is required for mTORC2 complex assembly and the mSIN1, but not PROTOR, interaction with RICTOR. 70 Mutation of the analogous residue in Caenorhabditis elegans, Gly1120, leads to a loss of function of RICTOR, indicating the importance of this residue for RICTOR, whose function is highly conserved. 71, 72 In addition, the function of RICTOR is regulated by multisite acetylation, and p300-mediated acetylation increases mTORC2 activity, as measured by AKT phosphorylation. 73 The domain required for acetylation is adjacent to a stability domain required for the interaction of RICTOR with mSIN1 and mLST8. 73 
EVOLUTION OF THE TOR PATHWAY IN EUKARYOTES
Saccharomyces cerevisiae Unlike in mammals where there is only one mTOR gene, in yeast there are two TOR encoding genes, TOR1 and TOR2. 2 Either TOR1 or TOR2 can be incorporated into TORC1, whereas TOR2 can only be incorporated into TORC2. 74 TOR1 mutants are viable, while TOR2 mutants are lethal. 75, 76 TORC1 is composed of TOR1 or TOR2, LST8, KOG1 (RAPTOR) and TCO89. 74, 77 Notably, TCO89 does not have any homologs in higher eukaryotes 34 and at this time its functional equivalent, if any, is unknown. TORC2 is composed of TOR2, AVO1, AVO2, AVO3, LST8 and BIT61. 74, 77 AVO3 is the yeast homolog of RICTOR, while AVO1 shares limited homology to the mammalian protein mSIN1. 34 AVO2 and BIT61 seem to exist only in S. cerevisiae. 34 Another unique feature of the TOR pathway in S. cerevisiae is the lack of both RHEB and the TSC complex. 1 The similarities and differences in components of the pathway and regulatory mechanisms in various eukaryotic species are shown in Figure 2 . TORC1 controls protein translation and subsequent cellcycle progression from the G1 phase. 78 SCH9 is an AGC kinase that is an important downstream effector of TORC1 in S. cerevisiae that functions similarly to S6K in mammals.
79 TORC1 in yeast, like mammals, can also inhibit the induction of autophagy.
80 TORC2 controls the polarization of the actin cytoskeleton during cell-cycle progression. 81 It should be also noted that TORC2 in yeast regulates the actin cytoskeleton through PKC1. 74, 82 Caenorhabditis elegans A characteristic feature of the mTOR pathway in C. elegans is the absence of the TSC complex. 83 In this case, AKT activity and TORC1 are linked by AKT's control on DAF-16 (FOXO)-dependent transcriptional regulation of DAF-15 (RAPTOR). 83 Deletion of ceTOR leads to developmental arrest at L3 larval stage, intestinal atrophy, and shares some characteristics with starved L3 larvae. 84 DAF-15 (RAPTOR) mutants have a similar phenotype with ceTOR mutants, 83 while knockdown of ceTOR or DAF-15 in adulthood leads to an increased lifespan. 83, 85 In addition, knockdown of S6K or eIF4G leads to increased lifespan, which indicates a role for protein translation as an important downstream TOR effector in aging of C. elegans. 86, 87 Loss of TORC1 leads to the induction of autophagy and autophagy is required for an increase in lifespan. 88 ceRICTOR mutants that are associated with a loss of TORC2, are characterized by high-body fat, developmentally delayed growth, decreased fecundity and a shorter lifespan. 71, 72 Importantly, effects of RICTOR were mediated via SGK1 engagement and not through the AKT/Daf-16 (FOXO) axis. 71 PKC was also not involved, as PKC mutants do not mimic ceRICTOR mutants. 71 Interestingly, C10H11.8 (LST8) mutants mimic ceRICTOR mutants even though LST8 is present in both complexes. 71 Unlike VPS34's regulatory effects on mTORC1 signaling, siRNA against VPS34 did not recapitulate the phenotype of DAF-15 or TOR mutations, indicating that it does not play a role in TOR signaling in C. elegans.
89
Drosophila melanogaster In flies, TOR knockouts have a similar phenotype to amino acid deprived larvae, characterized by developmental arrest and lipid vesicle aggregation. 90, 91 In the adult fly, inhibition of the TOR pathway results in the extension of lifespan.
92 4E-BP1 is an important downstream TOR effector for this process. 93 Like in Figure 2 . Similarities and differences in TOR signaling among eukaryotes. Despite many similarities in patterns of expression and functional outcomes, there are several differences in the TOR pathway among different eukaryotes. The same shape and color indicates that a given element is homologous throughout the different organisms. (a) In the yeast S. cerevisiae, the unique components are TCO89, AVO2 and BIT63 and they lack the TSC complex and RHEB. Yeast also does not have a PI3K axis as part of TORC2. S. cerevisiae has two TOR genes, TOR1 and TOR2, both of which can be part of TORC1, while TOR2 can only be part of TORC2. (b) In C. elegans, TORC1 includes RAPTOR and LST8 homologs, while TORC2 includes RICTOR and LST8 homologs. The TSC complex is missing, but TORC1 activity can be controlled by AKT through DAF-16 transcriptional regulation of DAF-15 (RAPTOR) expression. (c) The D. melanogaster TOR pathway is quite similar to mammals; however, it lacks some of the components of the mTORC1 and mTORC2 complexes like in C. elegans. VPS34 in D. melanogaster does not regulate TORC1 but is placed downstream of TORC1. TORC1 inhibits it through ATG1 (ULK1) to inhibit autophagy. (d) The mTOR pathway in mammals is by far the most complex with multiple unique components and signaling inputs.
C. elegans, VPS34 is not linked to TOR signaling in D. melanogaster, as VPS34 null flies have no defects in TOR signaling. 94 Recruitment of VPS34 in autophagosome formation requires inhibition of TOR and activation of ATG1 (ULK1 in flies) signaling, indicating that VPS34 is downstream of TOR. 94 It should be noted that VPS34 seems to play a conserved role in autophagy and vesicle trafficking in mammals, yeast and flies. 94, 95 The role of VPS34 in TOR signaling is not conserved in lower eukaryotes and may have evolved as a mechanism of regulation later on. D. melanogaster has only one sestrin gene, and like in mammals, was shown to be a regulator of AMPK/TOR signaling. 96 
Mammals
The DEPTOR, PRAS40 and PROTOR components of the pathway are only found in mammals. Knockout of mTOR in mice is embryonic lethal. [97] [98] [99] The knockout of certain components of the mTORC2 complex is also embryonic lethal. 62, 100 It should be noted that S6K mutants in worms, flies and mice show inhibition of growth, reduced body size and slightly delayed development, but unlike TOR, S6K mutants can survive embryogenesis, indicating S6K does not play as critical a role in development. 84, [101] [102] [103] In fact, in S6K1/2 double knockout mice, it was shown that some of these mice die at or shortly after birth, while others make it to adulthood, and those that died had no gross developmental defects. 102 Like in the worm, mLST8 mutant mice embryos display the same phenotype of RICTOR knockout embryos, whereas RAPTOR and mTOR knockout mouse embryos share similar characteristics. 62 This indicates that mLST8 is more crucial for mTORC2 assembly and function than it is for mTORC1, but the reasons for this are unknown at this time and this requires further investigation.
The role of mTORC2 in cytoskeletal rearrangement and motility in mammals is still not well understood. Knockdown of mTOR, mLST8 or RICTOR inhibits cell spreading and actin polymerization. 104, 105 Expression of active RAS-related C3 botulinum toxin substrate 1 (RAC1) was able to restore the actin cytoskeletal defects in mTOR, mLST8 or RICTOR knockdown cells. 104 Interestingly, RAC1 seems to be required both upstream and downstream of mTORC2, as it regulates both mTORC2 localization and the downstream actin polymerization effects. 104, 106 Knockdown of RICTOR or mTOR leads to a decrease in phosphorylation of PKCa, 105 implicating this member of the PKC family of proteins in mTORC2 signaling. It should be also noted that a recent study suggested that RICTOR may have effects on the cytoskeleton outside of mTORC2 as RICTOR knockdown, but not mSIN1 knockdown, suppressed RhoGDI2, a negative regulator of cell migration. 107 
FEEDBACK LOOPS AND NEGATIVE REGULATORS OF THE mTOR PATHWAY
The regulation of the TOR pathway is highly complex due to the existence of multiple negative feedback regulatory loops (Figure 3) . Several studies have shown a negative effect of mTORC1 on the insulin-PI3K-AKT pathway axis.
103,108,109 S6K1 can suppress insulin receptor substrate 1 (IRS1) function through direct phosphorylation of the protein at multiple sites, 103, 108 and it can also inhibit IRS1 expression at the transcriptional level. 108, 109 The resulting impaired adaptor function of IRS1 leads to inhibitory effects on the insulin-PI3K-AKT pathway. Recently, a new substrate of mTOR, growth factor receptor-bound protein 10 (GRB10), was discovered, independently by two groups, using a phospho-proteomic analysis approach. 110, 111 These studies demonstrated that GRB10 is an mTORC1 effector that suppresses insulin/growth factor-receptor generated-signals and negatively controls mitogenic pathways. 110, 111 After its phosphorylation by mTOR, GRB10 is activated and inhibits the insulin receptor (IR), thus blocking PI3K-AKT signaling. 110, 111 A relatively recent study highlighted a new regulatory loop that exists between AKT, FOXO1 and mTOR. 112 In a TSC2-dependent manner, FOXO1 was shown to activate AMPK via transcriptional upregulation of Sestrin3, leading to a decrease in mTORC1 activity and activation of AKT via suppression of the S6K feedback loop. 112 Then via a TSC2-independent mechanism, FOXO1, independent of its ability to bind DNA, was found to increase the levels of RICTOR, leading to an increase in mTORC2 formation and activation of AKT. 112 Other feedback loops with regulatory effects on mTOR functions involve the TSC/RHEB axis. RHEB activates mTORC1, but has the opposite effect on mTORC2 and its activity results in inhibition of AKT. 113 Most likely this involves the S6K feedback loop. TSC1/2 has the opposite effect where it traditionally inhibits RHEB/mTORC1, but it can activate mTORC2, possibly by relieving the negative feedback loop. 113 However, another study has demonstrated that TSC2 can directly interact with mTORC2 through RICTOR to activate the complex independently of its effects on mTORC1.
114 mTORC1 can also inhibit mTORC2 in a negative feedback loop through S6K, where S6K directly phosphorylates RICTOR at Thr1135. 115 Importantly, the phosphorylation on Thr1135 only effects mTORC2-mediated phosphorylation of AKT but not SGK or PKCa. 115 This phosphorylation site is only found in mammals, and therefore it is not evolutionally conserved. 115 DEPTOR is a negative regulator of mTOR and can inhibit both mTORC1 and mTORC2. 116 It is well established from previous work that mTORC1 positively regulates adipogenesis. 117 Recent evidence has shown that DEPTOR, though it negatively regulates mTOR, also positively regulates adipogenesis by suppressing the Figure 3 . Feedback loops in the mTOR pathway. S6K can inhibit insulin/PI3'K signaling through inhibition of IRS1. mTORC1 activates GRB10 which inhibits both MAPK and PI3K pathways through effects on growth factor receptors such as the IR. mTORC1 can inhibit MNK/ eIF4E, although the exact mechanism is unknown; however, MAPK signaling could be effected through the S6K/IRS1 feedback loop. The MAPK pathway can inhibit PI3K and downstream signaling through inhibition of either EGFR or IRS1. ERK can activate mTORC1 via inhibition of the TSC complex, while S6K can inhibit mTORC2 through direct phosphorylation of RICTOR by S6K. The TSC complex while it inhibits mTORC1 can activate mTORC2. AKT inhibits FOXOs, and FOXOs can activate AMPK by promoting Sesn3 expression, thereby inhibiting mTORC1. FOXOs can also activate mTORC2 via increased expression of RICTOR; however, this mechanism is not through FOXO1's ability to bind DNA. AKT can activate mTORC1 via inhibition of the TSC complex. DEPTOR can inhibit mTORC1 and thus relieve the S6K/IRS1 feedback loop. Various classes of drugs are shown in green color that can be used to target the pathway as well as feedback loops, and potentially enhance the therapeutic efficacy of mTOR effectors.
mTORC1/S6K feedback loop on the insulin pathway. 118 This leads to peroxisome proliferator-activated receptor-g activation through AKT to increase adipogenesis, and it is associated with increased obesity in mice and humans when DEPTOR is overexpressed. 118 Mitogen-activated protein kinase (MAPK)-interacting kinases (MNKs) are downstream effectors of MAPK pathways and are known to phosphorylate eIF4E on Ser209, a site whose phosphorylation correlates with induction of cell growth and proliferation. 119, 120 There is evidence for a feedback loop induced during mTOR inhibition that results in activation of the MNK/eIF4E pathway. It has been shown that in cells treated with the mTORC1 inhibitor rapamycin, eIF4E is phosphorylated in a MNK-dependent manner. 121, 122 This indicates that the mTOR pathway inhibits MNK and eIF4E via a negative feedback loop. The inhibition of MNK by mTOR may be dependent on PI3K, as in PI3K-deficient cells there was no activation of MNK/eIF4E when they were treated with rapamycin. 122 A proposed mechanism of MAPK inhibition by mTORC1 was through the S6K-IRS1 feedback loop. 123 The recent discovery of GRB10 110, 111 may also shed some light on the mechanism. It is possible that the inhibitory effects of activated GRB10 on growth factor receptors may account for its suppressive effects on MNK/eIF4E phosphorylation, via modulation of MAPK pathways. Such engagement of MAPK pathways may have clinical implications, as in a phase I clinical trial, 50% of cancer patients treated with the rapalog everolimus had activation of the MAPK pathway as measured by ERK phosphorylation in biopsy samples, indicating that a feedback loop between mTORC1 and the MEK/ ERK pathway is induced in vivo. 123 Similarly, MAPK pathways can also negatively regulate the PI3K-mTOR-AKT pathway, as treatment with MEK inhibitors leads to activation of AKT. 124, 125 One feedback loop that exists involves suppression of MEKdependent inhibition of the epidermal growth factor receptor (EGFR) and associated suppression of EGF-dependent PI3K/AKT activity. 125 An additional mechanism involves suppression of ERKdependent inhibition of IRS1, thus effecting signaling through insulin-like growth factor activation of PI3K/AKT. 124 mTOR and cancer There has been extensive evidence that mTOR plays an important role in tumorigenesis, and aberrant activation of the mTOR pathway promotes the growth and survival of various types of malignant cells. 9, 15, 126 There are multiple familial cancer syndromes that lead to hyperactivation of the mTOR pathway. The LKB1 tumor suppressor is lost in Peutz-Jegher's syndrome, leading to intestinal polyps and an increased risk for the development of certain cancers. 127, 128 Approximately 50% of NSCLC (non-small cell lung cancer) tumors harbor mutations in LKB1. 129 It is well established that LKB1 is the key kinase responsible for activating AMPK. 130 Inactivating mutations in LKB1 result in a lack of AMPK activation with an associated upregulation of mTORC1 activity, as mTORC1 signaling has been shown to be hyperactivated in LKB1-deficient mouse embryonic fibroblasts and livers as well as in hamaratomas from LKB1 heterozygous mice. 131 Tuberous sclerosis (TS), another familial cancer syndrome that is characterized by hamartomas and benign tumors in various organs, is caused by mutations in TSC1 or TSC2. [132] [133] [134] [135] Interestingly, while double knockout of TSC1 or TSC2 is embryonic lethal, heterozygous mice are viable and develop renal tumors, hemangiomas or leiomyomas. 136, 137 Loss of the TSC complex leads to a decrease in mTORC2 signaling, indicating that the benign nature of TS tumors may be due to only mTORC1 activation. 114 However, specific knockout of TSC1 in the liver leads to the development of hepatocellular carcinoma in mice and follows a similar progression as seen in human hepatocellular carcinoma. 138 These tumors are characterized by chronic activation of the mTORC1 pathway and inhibition of autophagy, leading to liver damage and inflammation. 138 TSC1 knockout in this case may promote tumorigenesis because inhibition of autophagy by mTOR may be enhancing tumor progression in the liver, whereas in other tumor types it may be protective. 139 Recently, a third member of the TSC complex has been discovered called TBC1D7 and was shown to be required for inhibition of mTORC1. 140 Since B15% of TS patients do not have mutations in either TSC1 or TSC2, it was proposed that TBC1D7 could be a third TSC gene. 140, 141 However, after genetic analysis no changes were observed in the TBC1D7 gene, indicating it is not mutated in TS. 140 Outside of the familiar cancer syndromes, there is evidence that deregulation of other elements of the mTOR pathway play important roles in the growth and survival of many malignancies. Activating mutations in PI3K or deletion of phosphatase and tensin homolog (PTEN) occur frequently in malignancies and result in activation of AKT and mTOR. 142 RHEB is overexpressed in some human lymphomas and leads to the development of aggressive lymphomas in a transgenic mouse model. 143 The eukaryotic initiation factor eIF4E, which is downstream of the mTOR pathway can act as an oncogene by transforming cells in vivo, 144, 145 and its overexpression has been associated with a poor prognosis in several human malignancies. 126 In addition, loss of 4E-BP1, which suppresses eIF4E function, leads to increased tumorigenesis, 146 while overexpression of constitutively activated 4E-BP1 suppresses the growth of tumors in vivo.
147,148 RICTOR expression is required for the growth of multiple cancer cell types in vitro and in vivo. [149] [150] [151] There is a frequent loss of heterozygosity in the gene region of PROTOR-1 in human breast cancer and PROTOR-1 is downregulated in a subset of breast tumors and cell lines. 152 As mentioned above, DEPTOR inhibits mTORC1 but can also activate PI3K/AKT signaling by relieving the S6K/IRS1 negative feedback loop. 116, 118 Therefore, DEPTOR can be pro-tumorigenic by promoting cell survival through PI3K/AKT, and is overexpressed in multiple myeloma, hepatocellular carcinoma and thyroid carcinoma. 116, [153] [154] [155] The mTOR pathway has also been shown to be activated in myeloid leukemia, including BCR-ABL transformed cells, and plays a role in their growth and survival. [156] [157] [158] [159] [160] [161] Medulloblastoma is a pediatric brain tumor of the cerebellum that can be classified into four distinct molecular subtypes based upon mutations/pathway activation, Hedgehog (Hh), WNT, Group 3 and Group 4. [162] [163] [164] [165] [166] The PI3K/mTOR pathway has been implicated in the tumorigenesis of 3 of the 4 subtypes, Hh, WNT and Group 3. In the Hh pathway subtype, there is evidence for the extensive involvement of PI3K/mTOR pathways in tumorigenesis of this subtype of medulloblastoma. In a Hh-driven mouse model of medulloblastoma metastasis, activation of the PI3K signaling pathway was associated with dissemination of the primary tumor into the spinal column.
167 PI3K/mTOR activation was also associated with resistance to Hh pathway inhibitors in Hh-driven mouse models of medulloblastoma. 168 Combined treatment with a dual PI3K/mTOR inhibitor and an inhibitor of the hedgehog pathway was able to overcome this resistance. 168 Activation of PI3K signaling was also associated with survival of the stem cells after radiation exposure in Hh-driven mouse models of medulloblastoma, suggesting its involvement in relapse of medulloblastoma patients after radiation treatment. 169 Within the WNT subtype of medulloblastoma, crosstalk between the PI3K and WNT pathways has been shown to be important as PI3K inhibition of GSK-3b enhances b-catenin activity, and treatment with a PDK inhibitor reduced the growth of medulloblastoma xenografts in mice.
170 PIK3CA gene mutations have been found in multiple subtypes of medulloblastoma patients. 165, 171 When the PIK3C(E545K) gene mutation was combined with a WNT-driven mouse model of medulloblastoma, the mice showed accelerated tumor development and enhanced mTOR activity, as measured by rpS6 and 4EBP-1 phosphorylation. 165 These studies indicate that the PI3K/mTOR pathway activation promotes WNT-driven medulloblastoma tumorgenesis. A majority of the group 3 tumors are characterized by c-MYC overexpression and have the worst prognosis. 164, 172, 173 A recent mouse model of this subtype was developed by transplanting c-MYC and dominant negative p53 expressing cells into the cerebellum of donor mice. 174 These tumors had activation of the PI3K pathway and were sensitive to the dual PI3K/mTOR inhibitor. 174 TARGETING THE mTOR PATHWAY Rapamycin and rapalogs Rapamycin was the first mTOR inhibitor that was originally discovered and purified in 1970s. 175 Despite its antitumor activity in preclinical models, rapamycin has not been successfully developed as an anticancer agent, among other reasons due to poor solubility and stability. 126 Other analogs of rapamycin have been developed and in phase II and III trials, temsirolimus and everolimus showed efficacy in treating RCC (renal cell carcinoma), neuroendocrine tumors and mantle cell lymphoma. [176] [177] [178] [179] Currently, everolimus and temsirolimus are approved for the treatment of RCC. 180 Recently, everolimus was also approved by the FDA for the treatment of progressive advanced hormone receptor-positive, HER2-negative, breast cancer in combination with examestane, based on the results of a pivotal trial that showed important clinical activity. 181 Due to the prevalent activation of mTOR in cancer, one would expect rapalogs to be more effective in inhibiting a wide variety of tumors, but this does not appear to be the case. In glioblastoma, in both preclinical models and clinical trials, PTEN mutations did not predict response to rapalogs. 182, 183 In NSCLC, LKB1 mutations in lung cancer cell lines also did not predict response to rapamycin. 129 Traditionally, only mTORC1 is sensitive to rapamycin, as FKBP12-rapamycin cannot bind to mTORC2. 104, 105 There is also evidence for rapamycin-insensitive mTORC1 (RI-mTORC1) in BCR-ABL expressing leukemia cell lines. 156 Other studies have also demonstrated that rapamycin only partially inhibits mTORC1, as measured by an incomplete block of 4E-BP1 phosphorylation, [184] [185] [186] suggesting the existence of RI-mTORC1 signals. Therefore, the relative limitations in clinical value of rapalogs may reflect activation of the pathway at other nodes due to non-effectiveness, or by relieving negative feedback loops. Another issue that may affect the activity of rapalogs is that inhibition of mTOR can lead to induction of autophagy. In cancer cells, autophagy can be both anti-and pro-tumorigenic depending on the context and stimulus. 139 Autophagy was recently shown to be a mechanism of resistance to cell death in RCC cell lines treated with the rapalog temsirolimus. 187 Co-treatment with an autophagy inhibitor increased cell death and suppressed xenograft growth in mice. 187 This indicates that combining rapalogs with autophagy inhibitors in RCC may further increase their therapeutic potential and clinical efficacy, but this remains to be directly examined in future trials.
Catalytic mTOR inhibitors Due to the limited success of rapalogs, mTOR catalytic inhibitors have been developed that target both mTORC1 and mTORC2. These inhibitors show superior anti-tumorigenic effects compared with rapalogs in preclinical evaluations, due to their ability to block both mTORC1 as well as mTORC2.
188 PP242 and OSI-027 both showed superior anti-leukemic effects compared with rapamycin in BCR-ABL expressing cell lines, 156, 157 as well as a BCR-ABL positive leukemia mouse model. 157 Treatment of acute myeloid leukemia cells with OSI-027 also showed superior antileukemic effects against cell lines as well as primary patient samples. 189 OSI-027 was able to completely block 4E-BP1 phosphorylation and was much more effective in blocking mRNA translation in leukemia cells, as compared with rapamycin. 189 The drawback with dual catalytic inhibitors, like rapalogs, is that the mTORC1 feedback loops can still be relieved leading to activation of PI3K or MAPK signaling. AKT can also still be activated at the Thr308 residue despite mTORC2 inhibition. 185 As in the case of rapalogs, catalytic inhibitors can also induce autophagy. In BCR-ABL positive leukemia, the co-treatment of OSI-027 with the autophagy inhibitor chloroquine enhanced the anti-leukemic effects of OSI-027 alone. 156 Therefore, combined treatment of certain cancers with a catalytic inhibitor and an autophagy inhibitor may ultimately prove to be a better therapeutic strategy.
Dual PI3K/mTOR inhibitors The concerns over mTOR inhibitors led to the development of dual PI3K/mTOR kinase inhibitors. As mentioned previously, PI3K and mTOR have high homology in their kinase domains, so development of dual inhibitors was possible. 15 Two inhibitors PI-103 or NVP-BEZ235 were found to strongly suppress both S6K and AKT and to induce apoptosis in gliomas, breast tumors and leukemia cells. 157, [190] [191] [192] [193] PI3K-mTOR dual inhibitors inhibit all input signals to AKT; however, they may not affect RAS mutant tumors as they can signal alternatively through the MEK-ERK pathway. 194 Co-treatment with a MEK inhibitor and a PI3K inhibitor was required for antitumorigenic responses in mutant RAS lung tumors in mice. 194 The BRAFV600E mutation that is found frequently in melanomas was shown to negatively regulate AKT via mTORC2, as it required RICTOR for inhibition of AKT activity, but independently of BRAF kinase activity and downstream MEK-ERK engagement. 195 Subsequent PTEN loss, however, was able to override the BRAFV600E inhibitory effects on AKT. 195 Therefore, melanomas with just BRAFV600E may respond well to MEK inhibition alone, whereas melanomas that have both PTEN loss and the BRAFV600E will likely require a combination of both PI3K and MEK inhibition for optimal results. 195 In LKB1 or LKB1/ KRAS mutant tumors, the triple combination of a SRC inhibitor, Dual PI3K/mTOR inhibitor and MEK inhibitor was required to achieve significant anti-tumor effects. 129 
CONCLUSIONS
Because of its central role in cell metabolism and other important functions, the mTOR pathway has emerged as a major target for the treatment of malignancies. There is evidence for deregulation of mTOR, or upstream and/or downstream effectors of the pathway, in several human malignancies, and this has led to extensive efforts towards the development of mTOR targeting antineoplastic agents. The complexities of the mTOR pathway warrant further investigation in order to tease out the intricacies and inherent contradictions of the specific pathway member's roles and their regulation. The existence of multiple feedback loops and crosstalk with other pathways makes it difficult to target it effectively in cancer. Based on what we know now, it is unlikely that mTOR inhibitors as single agents will be proven curative in a wide array of patients. Multimodal treatment strategies will likely be required, where mTOR pathway inhibitors will be combined with other targeted agents. Such approaches warrant further development and clinical evaluation. However, one should also keep in mind that combinations of multiple agents may lead to additional toxicities. Another important clinical goal will be to identify potential responders to mTOR inhibitors or combinations based on the presence of genetic mutations and or other evidence for altered signaling pathways within a given tumor. With the rapid advances in the fields of genomics and proteomics, there is optimism that among other areas, personalized approaches for the treatment of cancer patients will be able to successfully incorporate drugs that target mTOR.
